Source of business for leading IL-17 agents in psoriasis varies significantly by brand. While the majority of Cosentyx patients are previously treated with a TNF inhibitor, a sizable portion of Taltz patients have tried another IL-17 agent before starting Taltz. This finding suggests a preference in the market for trying Cosentyx ahead of Taltz after a patient switches from a TNF agent.
CRA analytics insight
- Over 60% of Cosentyx patients were previously treated with a TNF agent, showing a strong presence for Cosentyx as a second line biologic agent in psoriasis following TNFs
- Nearly 30% of Taltz patients were previously treated with another IL-17 biologic, suggesting it is often the second choice IL-17 biologic in psoriasis
CRA not only uncovers new trends in data, but delves deeper to illuminate the “why” behind the findings. To learn more, contact Eddie Li and Travis Ruch.
